We are excited to announce a new official distributor: Bayber, who will commercialize our robotic exoskeleton in Portugal. This partnership marks another important milestone in our mission to democratize access to robotic rehabilitation across Europe.
We’re launching a new clinical study to evaluate the ABLE Daily, our exoskeleton designed to promote physical activity at home and in the community, and we’re looking for Dutch participants!
The ABLE Exoskeleton is now officially approved for use with Multiple Sclerosis (MS) and Neuromuscular Disorders.
Orthostatic hypotension (OH) is a cardiovascular disorder characterised by a significant drop in blood pressure after a change of position. Rehabilitation can reduce OH sypmtoms.
Marc Roma, after a motocross accident, walks again with the ABLE Exoskeleton, showcasing the powerful impact of determination and technology in rehabilitation.
Here we proudly and gratefully summarize the highlights of 2024.
